Grading of endometrial cancer using
Aged
Cluster Analysis
Discriminant Analysis
Endometrial Neoplasms
/ diagnostic imaging
Endometrium
/ pathology
Female
Humans
Least-Squares Analysis
Magnetic Resonance Spectroscopy
Metabolic Networks and Pathways
Metabolome
Metabolomics
Middle Aged
Models, Biological
Multivariate Analysis
Neoplasm Grading
Neoplasm Staging
Principal Component Analysis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 09 2021
13 09 2021
Historique:
received:
07
04
2021
accepted:
26
08
2021
entrez:
14
9
2021
pubmed:
15
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The tissue metabolomic characteristics associated with endometrial cancer (EC) at different grades were studied using high resolution (400 MHz) magic angle spinning (HR-MAS) proton spectroscopy. The metabolic profiles were obtained from 64 patients (14 with grade 1 (G1), 33 with grade 2 (G2) and 17 with grade 3 (G3) tumors) and compared with the profile acquired from 10 patients with the benign disorders. OPLS-DA revealed increased valine, isoleucine, leucine, hypotaurine, serine, lysine, ethanolamine, choline and decreased creatine, creatinine, glutathione, ascorbate, glutamate, phosphoethanolamine and scyllo-inositol in all EC grades in reference to the non-transformed tissue. The increased levels of taurine was additionally detected in the G1 and G2 tumors in comparison to the control tissue, while the elevated glycine, N-acetyl compound and lactate-in the G1 and G3 tumors. The metabolic features typical for the G1 tumors are the increased dimethyl sulfone, phosphocholine, and decreased glycerophosphocholine and glutamine levels, while the decreased myo-inositol level is characteristic for the G2 and G3 tumors. The elevated 3-hydroxybutyrate, alanine and betaine levels were observed in the G3 tumors. The differences between the grade G1 and G3 malignances were mainly related to the perturbations of phosphoethanolamine and phosphocholine biosynthesis, inositol, betaine, serine and glycine metabolism. The statistical significance of the OPLS-DA modeling was also verified by an univariate analysis. HR-MAS NMR based metabolomics provides an useful insight into the metabolic reprogramming in endometrial cancer.
Identifiants
pubmed: 34518615
doi: 10.1038/s41598-021-97505-y
pii: 10.1038/s41598-021-97505-y
pmc: PMC8438077
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18160Informations de copyright
© 2021. The Author(s).
Références
J Womens Health (Larchmt). 2019 Feb;28(2):237-243
pubmed: 30484734
Metabolites. 2020 Jul 31;10(8):
pubmed: 32751940
Biosci Rep. 2018 Aug 29;38(4):
pubmed: 30026261
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
J Carcinog. 2013 Jun 18;12:9
pubmed: 23858297
Gynecol Oncol. 2020 Jul;158(1):3-11
pubmed: 32331700
Cell Rep. 2014 May 22;7(4):1248-58
pubmed: 24813884
J Proteome Res. 2014 Dec 5;13(12):5281-92
pubmed: 25245235
Int J Cancer. 2016 Dec 1;139(11):2529-39
pubmed: 27486861
Cancer Res. 2014 Dec 1;74(23):6867-77
pubmed: 25267063
Bioinformatics. 2005 May 1;21(9):2088-90
pubmed: 15691857
Sci Rep. 2017 Aug 18;7(1):8803
pubmed: 28821813
J Clin Oncol. 2013 Jul 10;31(20):2607-18
pubmed: 23733771
Histopathology. 2020 Jan;76(1):52-63
pubmed: 31846532
Front Endocrinol (Lausanne). 2018 Mar 12;9:87
pubmed: 29593653
Front Immunol. 2018 May 24;9:1070
pubmed: 29881379
Cancer Res. 2010 Jul 15;70(14):5749-58
pubmed: 20570889
Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:129-139
pubmed: 27117028
Cell Biol Toxicol. 2021 Apr;37(2):261-275
pubmed: 32562081
Molecules. 2020 Apr 10;25(7):
pubmed: 32290029
Chin Med J (Engl). 2019 Jul 5;132(13):1550-1562
pubmed: 31268882
J Pharmacol Sci. 2016 Jun;131(2):101-9
pubmed: 27262903
Nucleic Acids Res. 2010 Jan;38(Database issue):D480-7
pubmed: 19948758
Nature. 2009 Feb 12;457(7231):910-4
pubmed: 19212411
Front Oncol. 2016 Dec 27;6:266
pubmed: 28083512
Am J Clin Nutr. 2007 May;85(5):1275-85
pubmed: 17490963
Genetics. 2011 Jun;188(2):461-77
pubmed: 21406679
Oncogenesis. 2017 Jul 31;6(7):e367
pubmed: 28759021
J Pathol. 2020 Mar;250(3):312-322
pubmed: 31829447
Front Nutr. 2018 Jul 10;5:61
pubmed: 30042948
PLoS One. 2019 Sep 18;14(9):e0222353
pubmed: 31532787
Gynecol Oncol Res Pract. 2016 Dec 13;3:14
pubmed: 27999680
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Lancet Oncol. 2014 Jun;15(7):e268-78
pubmed: 24872110
NMR Biomed. 2019 Oct;32(10):e4112
pubmed: 31184789
Biochim Biophys Acta. 2012 May;1821(5):754-61
pubmed: 21979151
J Assist Reprod Genet. 1992 Dec;9(6):524-30
pubmed: 1299385
Pathobiology. 2018;85(1-2):35-40
pubmed: 28614814
Metabolomics. 2019 Oct 29;15(11):146
pubmed: 31664624
Oncotarget. 2014 Nov 30;5(22):11004-13
pubmed: 25436979
Am J Surg Pathol. 2005 Mar;29(3):295-304
pubmed: 15725797
Hum Reprod. 2016 Apr;31(4):854-65
pubmed: 26851602
Cancer Sci. 2018 Apr;109(4):1032-1043
pubmed: 29436067
Int J Mol Sci. 2020 Aug 23;21(17):
pubmed: 32842547
Cell Rep. 2019 Oct 1;29(1):89-103.e7
pubmed: 31577958
J Proteome Res. 2011 Aug 5;10(8):3513-21
pubmed: 21661735
Gynecol Oncol. 1996 Feb;60(2):277-82
pubmed: 8631551
Curr Opin Clin Nutr Metab Care. 2018 Jan;21(1):64-70
pubmed: 29211698
Acta Radiol. 2018 Apr;59(4):497-505
pubmed: 28927296
Anal Chem. 2008 Jan 1;80(1):115-22
pubmed: 18027910
Gynecol Oncol. 2006 Oct;103(1):253-60
pubmed: 16650464
Cancer. 2002 Sep 1;95(5):1055-63
pubmed: 12209691
Cancer Metab. 2018 Apr 3;6:3
pubmed: 29619216
Metabolites. 2019 Jan 22;9(2):
pubmed: 30678289
Oncotarget. 2017 Jun 13;8(24):38541-38553
pubmed: 28404949
NMR Biomed. 2012 Sep;25(9):1033-42
pubmed: 22279038
Cancer Res. 2005 Oct 15;65(20):9369-76
pubmed: 16230400
Cancer Discov. 2014 Dec;4(12):1406-17
pubmed: 25186948
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74
pubmed: 30550484
Semin Cell Dev Biol. 2015 Jul;43:22-32
pubmed: 26277542
Sci Rep. 2018 Apr 24;8(1):6466
pubmed: 29691425
Molecules. 2020 Nov 04;25(21):
pubmed: 33158172
Cancer Discov. 2014 Dec;4(12):1371-3
pubmed: 25477105
EPMA J. 2018 Feb 21;9(1):77-102
pubmed: 29515689
J Mol Med (Berl). 2020 Feb;98(2):161-177
pubmed: 31970428
EXCLI J. 2019 Dec 19;18:1097-1098
pubmed: 31938028
NMR Biomed. 2018 Aug;31(8):e3936
pubmed: 29928787
Int J Clin Oncol. 2014 Apr;19(2):364-72
pubmed: 23700142
Trends Biochem Sci. 2014 Apr;39(4):191-8
pubmed: 24657017